| Biomarker ID | 478 |
| PMID | 19854485 |
| Year | 2010 |
| Biomarker | Clusterin and Clusterin Density |
| Biomarker Basis | Concentration Based (μg/ml) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated: Clusterin [(BPH: 94.2 ± 38.7) Vs (PCA: 137.2 ± 36.6 )]; Clusterin Density [(BPH: 3.2 ± 2.2 ) Vs (PCA: 5.5 ± 2.6 )] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Myc repressed pathway,Response to elevated platelet cytosolic calcium,Platelet activation, signaling and aggregation,BDNF signaling pathway,FSH regulation of apoptosis |
| Experiment | Benign Prostatic Hyperplasia Vs Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | Sera were obtained from 380 patients with prostate cancer and 120 with benign prostatic hyperplasia. Of the 380 prostate cancer patients, 162 underwent radical prostatectomy and pelvic lymphadenectomy, and 104 and 58 were diagnosed as having organ-confined and extraprostatic diseases, respectively. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | sandwich enzyme immunoassay |
| Clinical | No |
| Remarks | Clusterin density was determined by dividing the serum clusterin level by the prostate volume |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CLU |